Iridex Earnings Call Signals Turnaround Amid Margin Strain

Iridex ((IRIX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Iridex’s latest earnings call painted a picture of an operational turnaround beginning to take hold, even as profit margins and selected regions remain under pressure. Management highlighted accelerating revenue growth, cost cuts, positive adjusted EBITDA, and operating cash generation, but balanced this with caution around tariffs, inventory write-downs, and geopolitical headwinds that are shaping a deliberately conservative outlook.

Broad-Based Revenue Growth in 2025

Iridex reported fiscal 2025 revenue of $52.7 million, an 8% increase from 2024, underscoring steady expansion across its core businesses. Growth was broad-based, spanning Cyclo G6 glaucoma, medical and surgical retina products, and both U.S. and international markets, signaling that the recovery is not reliant on a single franchise or geography.

Q4 Delivers the Strongest Growth of the Year

Fourth-quarter revenue reached $14.7 million, up 16% year over year, making it the fastest-growing quarter of 2025, albeit aided by a 14-week reporting period. The surge was driven primarily by higher retina and glaucoma probe sales, indicating strong procedural demand even as some capital equipment placements showed pockets of softness.

Profitability Edges Toward Break-Even

The company posted positive adjusted EBITDA of $817,000 for 2025, modestly higher than the prior year’s $611,000, marking an important psychological and operational milestone. Net loss narrowed sharply to just $0.2 million, or $0.01 per share, while Iridex also generated positive operating cash flow in Q4, bolstering confidence in the sustainability of its cost and revenue actions.

Deep Cost Cuts and New Savings Initiatives

Operating expenses fell 22% for the full year, with Q4 opex down 10% to $5.5 million versus the prior-year quarter, reflecting disciplined cost control. Management is layering on further savings via relocation of certain G&A functions, expected to add about $165,000 in quarterly savings from early 2026, and a planned headquarters move projected to trim fixed costs by roughly $600,000 annually.

Commercial and Product Momentum in Glaucoma and Retina

Glaucoma probe volumes rose solidly, with Q4 probe sales climbing to 15,900 from 13,300 a year earlier and full-year probes up 4% to 57,800, while G6 system placements grew 6% to 133 units. Retina was a standout, with Q4 retina revenue jumping 22% to $8.9 million, powered by PASCAL and medical and surgical retina systems, and the sales team converting about $1 million of opportunities around the AAO meeting.

Strengthening Balance Sheet and Cash Discipline

Cash and cash equivalents improved to about $6.0 million, up roughly $400,000 from the prior level of $5.6 million, supported by better cash conversion. Cash use for 2025 was $2.1 million, a 71% improvement from 2024, and management now expects further cash generation and positive full-year cash flow in 2026, suggesting less reliance on external funding.

Margin Compression Weighs on Profitability

Despite growth and cost cuts, gross margin slipped to 37% from 44%, with gross profit essentially flat at $5.5 million versus $5.6 million a year ago. The margin squeeze was tied to higher manufacturing costs, tariff-driven product cost increases, reduced capitalization of manufacturing overhead as inventories came down, and inventory write-downs that lowered reported profitability.

Geopolitics and Macro Headwinds Hit Key Regions

Management flagged the conflict in the Middle East, particularly Iran, as a meaningful drag on sales, enough that the region’s roughly 5% revenue contribution was excluded from 2026 guidance. Asia also proved challenging, with tariff uncertainty in China and currency weakness in Japan injecting volatility and complicating forecasting, reinforcing the conservative tone of the outlook.

Manufacturing Transition Brings Cost Upside and Risk

Higher product and manufacturing costs, including tariffs, are pressuring margins in the near term, prompting a strategic shift toward third-party contract manufacturing. Material production transfers are expected to start in 2026 with full implementation in 2027, a multi-year process that should ultimately support better margins but carries execution and timing risk during the transition period.

Localized Slowdowns in Capital Equipment Demand

Not all segments are moving in lockstep, as some capital equipment demand softened, with Q4 G6 systems sold slipping to 44 from 47 a year earlier. Germany saw purchase order delays and distributor changes, while PASCAL demand in the Middle East softened after large Q3 deliveries, underscoring that capital budgets remain uneven by region.

Inventory Adjustments Add to Margin Pressure

Inventory write-downs compounded the hit to gross margin, reflecting a more conservative stance on stock levels and product mix. At the same time, lower capitalization of manufacturing overhead, as inventories were reduced, shifted more costs directly into cost of goods sold, weighing on reported margins even as the balance sheet was being streamlined.

Conservative 2026 Outlook Reflects Regional Uncertainty

For 2026, Iridex guided revenue to $51.0–$53.0 million, explicitly assuming no contribution from the Middle East, which accounted for around 5% of revenue in 2025. On a comparable basis excluding that region, the outlook implies only about 1%–5% growth, reflecting management’s cautious stance amid geopolitical uncertainty and the gradual pace at which strategic initiatives, especially in manufacturing, will translate into growth and margin gains.

Forward-Looking Guidance and Margin Improvement Plans

Management reiterated typical seasonality, with roughly 22% of annual revenue expected in Q1 and Q4 likely remaining the strongest quarter, and forecast positive cash flow for fiscal 2026 with improvement after Q1. Adjusted operating expenses are projected at $19.0–$19.5 million, with incremental savings from G&A relocations and a subsequent HQ move, and gross margins are expected to improve as manufacturing transfers begin in 2026 and fully ramp by 2027, building on 2025’s $817,000 of adjusted EBITDA and reduced cash burn.

Iridex’s earnings call framed a company that is moving out of triage and into execution, with revenue growing, costs shrinking, and cash trends improving. Margin pressure, regional volatility, and manufacturing transition risk keep the near-term story cautious, but if management delivers on its cost and supply-chain plans, investors could see a more profitable, less volatile Iridex emerge over the next two years.